Agendia N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
09 jun 2011 - 08:00
Statutaire naam
Agendia N.V.
Titel
Agendia Announces Colorectal Cancer Research Collaboration with Leading Cancer Centers – MD Anderson Cancer Center and Netherlands Cancer Institute
Bericht
AMSTERDAM, THE NETHERLANDS, and IRVINE, CA, 09 June, 2011 – Agendia, a commercial-stage molecular cancer diagnostics company, announces today that it has entered into a research collaboration with The University of Texas MD Anderson Cancer Center, one of the world’s leading cancer centers and whose research program is considered one of the most productive in the world aimed solely at cancer, and the Netherlands Cancer Institute (NKI) with the aim of improving diagnosis and treatment options of colorectal cancer patients. The work is based on an approach toward integrating several genomic and proteomic technologies in order to study patterns of gene and protein expression in cancerous tumors that may, when combined, provide greater insight into the unique biology of individual patients’ tumors and why patients often have different prognosis and varied responses to the same treatment.
Colorectal cancer is a leading cause of cancer-related death worldwide, with more than 1.2 million new cases each year. Though early detection and better treatment options have resulted in improved prognoses for many patients, more than half of colorectal cancer patients still die from the disease. While past researchers have often looked at just one aspect of the cancer’s progression, the new integrated approach utilized by MD Anderson, NKI and Agendia will analyze colorectal cancer samples on multiple levels. Specifically the collaboration will study the active genome (gene expression), mutation status and protein activation measured in the same sample and combine results with pathological and clinical data.
Datum laatste update: 14 januari 2026